home / stock / argx / argx message board
Subject | By | Source | When |
---|---|---|---|
Looking good | Fred Kadiddlehopper | investorshub | 02/24/2021 2:20:34 PM |
Progress in Sub-cu Efgartigimod was discussed in some | Fred Kadiddlehopper | investorshub | 02/24/2021 2:19:32 PM |
3 Penny Stocks To Buy Or Sell Before | jonny_red | investorshub | 11/05/2019 8:13:01 PM |
* * $AGRX Video Chart 11-01-18 * * | ClayTrader | investorshub | 11/01/2018 9:46:41 PM |
Efgartigimod is a first-in-class antibody fragment designed for | riche | investorshub | 10/17/2018 8:09:07 AM |
Year targets !! | riche | investorshub | 10/02/2018 9:37:24 AM |
1-4 Dec 2018: Efgartigimod full Phase II$ ITP | riche | investorshub | 10/02/2018 8:02:22 AM |
https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over resc | riche | investorshub | 10/02/2018 8:01:07 AM |
Sorry, theWhat a JOKE!...SOLD 3.5M shares at $86.50 | riche | investorshub | 10/02/2018 7:56:30 AM |
https://clinicaltrials.gov/ct2/show/NCT03102593 | riche | investorshub | 10/02/2018 7:52:40 AM |
I don't think so...TOXIC FINANCING DEAL ....EU | Justfactsmam | investorshub | 09/24/2018 3:03:02 PM |
ARGX buy 75.10 | stocktrademan | investorshub | 02/11/2018 5:32:48 PM |
News, Short Squeeze, Breakout and More Instantly...
argenx SE Company Name:
ARGX Stock Symbol:
NASDAQ Market:
2024-04-18 12:15:04 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for ARGX on April 18, 2024 10:01AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $363.76 at issue of the analyst recommendation. The overall analyst consensu...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patien...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...